Literature DB >> 2491896

Chromosome pattern in juvenile chronic myelogenous leukemia, myelodysplastic syndrome, and acute leukemia associated with neurofibromatosis.

Y Kaneko1, N Maseki, M Sakurai, A Shibuya, T Shinohara, T Fujimoto, H Kanno, A Nishikawa.   

Abstract

We studied chromosomes of BM cells from four neurofibromatosis (NF) patients with leukemia. One patient had a normal diploid karyotype in the chronic phase of juvenile chronic myelogenous leukemia (JCML). When the the leukemia evolved into the accelerated phase, she had cells with 46,XX,-7,+der(7)t(3;7)(q21;p22); the abnormalities resulted in a partial 7p deletion. In another patient with JCML, BM cells in the accelerated phase had 45,XY,-7. The abnormal cells with monosomy 7 disappeared from the BM after chemotherapy but reappeared later in the course. Another patient developed refractory anemia with excess of blasts in transformation (RAEB-T) and had cells with 46,XX,-6,+r(6)(p23?q21?); the abnormalities resulted in partial 6p and 6q deletions. The other patient with ANLL had cells with 45,XX,-7. Our findings and review of data on nine other patients suggest that BM cells of NF patients with JCML in chronic phase have no microscopically detectable chromosome changes and that cells with chromosomal deletion emerge when JCML evolve into the accelerated or blast phase. Thus, deletion of the whole or part of certain chromosomes, such as chromosomes 6, 7, etc., may be an important step towards the evolution of JCML cells or the development of de novo acute leukemias in NF patients.

Entities:  

Mesh:

Year:  1989        PMID: 2491896

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

Review 1.  Myelodysplastic syndromes.

Authors:  I M Hann
Journal:  Arch Dis Child       Date:  1992-07       Impact factor: 3.791

2.  Chromosomes 17 and 22 involved in marker formation in neurofibrosarcoma in von Recklinghausen disease. A cytogenetic and in situ hybridization study.

Authors:  H J Decker; L A Cannizzaro; M J Mendez; S P Leong; H Bixenman; C Berger; A A Sandberg
Journal:  Hum Genet       Date:  1990-08       Impact factor: 4.132

Review 3.  Targeting oncogenic Ras signaling in hematologic malignancies.

Authors:  Ashley F Ward; Benjamin S Braun; Kevin M Shannon
Journal:  Blood       Date:  2012-08-16       Impact factor: 22.113

4.  Quantitative effects of Nf1 inactivation on in vivo hematopoiesis.

Authors:  Y Zhang; B R Taylor; K Shannon; D W Clapp
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

Review 5.  Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor.

Authors:  Sachiko Ezoe
Journal:  Int J Environ Res Public Health       Date:  2012-07-10       Impact factor: 3.390

Review 6.  Genetic predispositions and childhood cancer.

Authors:  K Shannon
Journal:  Environ Health Perspect       Date:  1998-06       Impact factor: 9.031

7.  Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study.

Authors:  C A Stiller; J M Chessells; M Fitchett
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.